AU2013252913A1 - Breast cancer prognosis, prediction of progesterone receptor subtype and|prediction of response to antiprogestin treatment based on gene expression - Google Patents

Breast cancer prognosis, prediction of progesterone receptor subtype and|prediction of response to antiprogestin treatment based on gene expression Download PDF

Info

Publication number
AU2013252913A1
AU2013252913A1 AU2013252913A AU2013252913A AU2013252913A1 AU 2013252913 A1 AU2013252913 A1 AU 2013252913A1 AU 2013252913 A AU2013252913 A AU 2013252913A AU 2013252913 A AU2013252913 A AU 2013252913A AU 2013252913 A1 AU2013252913 A1 AU 2013252913A1
Authority
AU
Australia
Prior art keywords
expression
gene
genes
treatment
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013252913A
Other languages
English (en)
Inventor
Todd KNUTSON
Carol LANGE
Jason Basil NIKAS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Minnesota System
Original Assignee
University of Minnesota Twin Cities
University of Minnesota System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Minnesota Twin Cities, University of Minnesota System filed Critical University of Minnesota Twin Cities
Publication of AU2013252913A1 publication Critical patent/AU2013252913A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2013252913A 2012-04-27 2013-03-15 Breast cancer prognosis, prediction of progesterone receptor subtype and|prediction of response to antiprogestin treatment based on gene expression Abandoned AU2013252913A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261639407P 2012-04-27 2012-04-27
US61/639,407 2012-04-27
PCT/US2013/032677 WO2013162776A1 (en) 2012-04-27 2013-03-15 Breast cancer prognosis, prediction of progesterone receptor subtype and|prediction of response to antiprogestin treatment based on gene expression

Publications (1)

Publication Number Publication Date
AU2013252913A1 true AU2013252913A1 (en) 2014-11-27

Family

ID=48045769

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013252913A Abandoned AU2013252913A1 (en) 2012-04-27 2013-03-15 Breast cancer prognosis, prediction of progesterone receptor subtype and|prediction of response to antiprogestin treatment based on gene expression

Country Status (14)

Country Link
US (1) US10501800B2 (enExample)
EP (1) EP2841594A1 (enExample)
JP (1) JP2015516155A (enExample)
KR (1) KR20150028232A (enExample)
AU (1) AU2013252913A1 (enExample)
CA (1) CA2871590A1 (enExample)
HK (1) HK1208057A1 (enExample)
IL (1) IL235351A0 (enExample)
MX (1) MX2014013044A (enExample)
NZ (1) NZ701652A (enExample)
PH (1) PH12014502410A1 (enExample)
RU (1) RU2014147625A (enExample)
WO (1) WO2013162776A1 (enExample)
ZA (1) ZA201407853B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1208057A1 (en) 2012-04-27 2016-02-19 Regents Of The University Of Minnesota Breast cancer prognosis, prediction of progesterone receptor subtype and prediction of response to antiprogestin treatment based on gene expression
US20140363425A1 (en) * 2013-03-13 2014-12-11 J. Dinny Graham Systems and methods for identifying cancers having activated progesterone receptors
US20150276767A1 (en) * 2014-03-12 2015-10-01 The University Of Sydney Systems and methods for identifying cancers having activated progesterone receptors
HK1246653A1 (zh) 2014-11-17 2018-09-14 Context Biopharma Inc. 奥那司酮延长释放组合物和方法
US10308676B2 (en) 2015-09-25 2019-06-04 Context Biopharma Inc. Methods of making onapristone intermediates
EP3389632A4 (en) 2015-12-15 2019-11-06 Context Biopharma Inc. AMORPHIC ONAPRISTON COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection
US10942183B2 (en) 2017-04-05 2021-03-09 Regents Of The University Of Minnesota Methods of detecting progesterone receptor and of detecting an expression level
EP3822368A1 (en) 2019-11-14 2021-05-19 Koninklijke Philips N.V. Assessment of pr cellular signaling pathway activity using mathematical modelling of target gene expression
JP2023518424A (ja) * 2020-03-17 2023-05-01 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 治療に対するレスポンダを決定するための方法およびシステム
JP7619556B2 (ja) * 2020-10-08 2025-01-22 藤倉化成株式会社 動脈病変を検出し、並びに、脳心臓血管障害、糖尿病、慢性腎臓病、又は固形癌を検出する、体液抗体バイオマーカー
US20250005743A1 (en) * 2023-06-30 2025-01-02 Mackay Memorial Hospital Method and system for identifying hormone receptor status

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001271579A1 (en) 2000-06-28 2002-01-08 University Technology Corporation Progesterone receptor-regulated gene expression and methods related thereto
US6750015B2 (en) * 2000-06-28 2004-06-15 Kathryn B. Horwitz Progesterone receptor-regulated gene expression and methods related thereto
HK1208057A1 (en) 2012-04-27 2016-02-19 Regents Of The University Of Minnesota Breast cancer prognosis, prediction of progesterone receptor subtype and prediction of response to antiprogestin treatment based on gene expression

Also Published As

Publication number Publication date
IL235351A0 (en) 2014-12-31
JP2015516155A (ja) 2015-06-11
KR20150028232A (ko) 2015-03-13
MX2014013044A (es) 2015-06-23
US10501800B2 (en) 2019-12-10
WO2013162776A1 (en) 2013-10-31
HK1208057A1 (en) 2016-02-19
RU2014147625A (ru) 2016-06-20
CA2871590A1 (en) 2013-10-31
ZA201407853B (en) 2015-12-23
PH12014502410A1 (en) 2015-01-12
NZ701652A (en) 2016-09-30
EP2841594A1 (en) 2015-03-04
US20130316992A1 (en) 2013-11-28

Similar Documents

Publication Publication Date Title
US10501800B2 (en) Breast cancer prognosis
Knutson et al. Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression
US12280066B2 (en) Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
US8877445B2 (en) Methods for identification of tumor phenotype and treatment
US20190134004A1 (en) Methods and compositions for treating breast and prostate cancer
JP6550045B2 (ja) 乳がんに由来する骨の転移がんの予後診断および処置のための方法
Irish et al. Amplification of WHSC1L1 regulates expression and estrogen-independent activation of ERα in SUM-44 breast cancer cells and is associated with ERα over-expression in breast cancer
Willis et al. Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs
US20240355476A1 (en) Methods and compositions related to triple-negative breast cancer
Chang et al. REST-repressed lncRNA LINC01801 induces neuroendocrine differentiation in prostate cancer via transcriptional activation of autophagy
Shishavan et al. Downregulation of miR-125a-5p leads to STAT3 increased expression in breast cancer patients
US10167516B2 (en) Six-gene biomarker of survival and response to platinum based chemotherapy in serious ovarian cancer patients
Thiel et al. Global expression analysis of endometrial cancer cells in response to progesterone identifies new therapeutic targets
US20250154597A1 (en) Transcriptional reprogramming differentiates active from inactive esr1 fusions in endocrine therapy-refractory metastatic breast cancer
Gilfillan et al. Breast tumors escape endocrine therapy by ER-independent mechanisms triggered by the coordinated activities of HER2/HER3 and deacetylated FOXA1
US10942183B2 (en) Methods of detecting progesterone receptor and of detecting an expression level
Campion Progesterone Receptor Isoform Signaling In Ovarian Cancer Cellular Senescence
Shou-Tung et al. Analysis of genetic alterations in plasma DNA from breast cancer patients: a possible molecular biomarker in early detection and prognosis of breast cancer
CA2939861A1 (en) Systems and methods for identifying cancers having activated progesterone receptors

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application